Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
MEK inhibitor
DRUG CLASS:
MEK inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
trametinib (330)
selumetinib (106)
binimetinib (68)
mirdametinib (30)
avutometinib (27)
BAY86-9766 (16)
CI-1040 (15)
tunlametinib (12)
AS703026 (5)
CH4987655 (3)
DS03090629 (3)
LNP3794 (3)
IMM-6-415 (2)
AZD8330 (1)
PD98059 (1)
BI 847325 (0)
GDC-0623 (0)
antroquinonol (0)
MEK Inhibitor (0)
MG-D-1509 (0)
NFX-179 (0)
PF-07799544 (0)
WX-554 (0)
SNR1611 (0)
trametinib (330)
selumetinib (106)
binimetinib (68)
mirdametinib (30)
avutometinib (27)
BAY86-9766 (16)
CI-1040 (15)
tunlametinib (12)
AS703026 (5)
CH4987655 (3)
DS03090629 (3)
LNP3794 (3)
IMM-6-415 (2)
AZD8330 (1)
PD98059 (1)
BI 847325 (0)
GDC-0623 (0)
antroquinonol (0)
MEK Inhibitor (0)
MG-D-1509 (0)
NFX-179 (0)
PF-07799544 (0)
WX-554 (0)
SNR1611 (0)
›
Associations
(670)
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + binimetinib + encorafenib
Sensitive: A1 - Approval
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
cetuximab + binimetinib + encorafenib
Sensitive: A1 - Approval
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
Non Small Cell Lung Cancer
BRAF V600E
Non Small Cell Lung Cancer
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
trametinib
Resistant: A1 - Approval
trametinib
Resistant
:
A1
trametinib
Resistant: A1 - Approval
trametinib
Resistant
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600E
Solid Tumor
BRAF V600E
Solid Tumor
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.